

## Full-Life Technologies to Present Research on FL-031 and FL-801 at AACR 2025

**Heidelberg, Germany, and Shanghai, China – April 22, 2025** – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced that the Company will present research on FL-031 and FL-801 at AACR 2025 annual meeting. Dr. Fa Liu, Chief Scientific Officer, will give two poster presentations on April 27, 2025, 2:00 PM CDT.

Details of these presentations are given in the table below:

Abstract Title	Presentation Information
<b>Discovery of FL-801, a B7-H3-Targeting Nanobody-based Radioligand Vector, Using Clear-X™ Linker Technology</b>	<b>Abstract ID:</b> 6929 <b>Track:</b> Experimental and Molecular Therapeutics <b>Session:</b> Theranostics and Radiotheranostics <b>Session Time:</b> Sunday, April 27, 2025. 2:00 PM CDT <b>Location:</b> Poster Section 25
<b>Preclinical development of [68Ga]Ga/[225Ac]Ac-FL-031 theranostic pair for the treatment of SSTR2-positive cancers</b>	<b>Abstract ID:</b> 6936 <b>Track:</b> Experimental and Molecular Therapeutics <b>Session:</b> Theranostics and Radiotheranostics <b>Session Time:</b> Sunday, April 27, 2025. 2:00 PM CDT <b>Location:</b> Poster Section 25

### About FL-801

FL-801 is a novel nanobody-based radionuclide drug conjugate ("RDC") vector targeting B7-H3 positive solid tumors. B7-H3 is an emerging immune checkpoint and therapeutic target with overexpression across various solid tumors. FL-801 RDCs have demonstrated favorable biodistribution profiles and encouraging anti-tumor activities in preclinical studies.

### About FL-031

FL-031 is a novel peptide-based vector targeting SSTR2 positive solid tumors. In preclinical studies, <sup>177</sup>Lu-FL-031 has shown promising biodistribution profiles and anti-tumor activity in both high and low SSTR2 expression cell-line-derived xenograft ("CDX") models. With the Ac-225-labeled FL-031 in preclinical development as a potential targeted alpha-therapy, Full-Life aims to expand the indication of SSTR2-targeted RDC therapies beyond gastroenteropancreatic neuroendocrine tumors ("GEP-NETs") to others including small cell lung cancer ("SCLC").

### About Full-Life Technologies

Full-Life Technologies ("Full-Life") is a fully integrated clinical-stage global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the

treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.

**Media Contacts:**

Full-Life

Email: [pr@t-full.com](mailto:pr@t-full.com)

Website: [www.full-life.com](http://www.full-life.com)